Gamida Cell $20 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Davis Polk advised the representative of the underwriters in connection with the $20 million SEC-registered follow-on offering of 12,905,000 ordinary shares of Gamida Cell Ltd. The ordinary shares are listed on the Nasdaq Global Market under the symbol “GMDA.”
Based in Jerusalem, Israel, Gamida Cell is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumor and blood cancers and other serious blood diseases.
The Davis Polk corporate team included partner Derek Dostal and associates Gil Savir, Claudia Carvajal Lopez, Tomer Magid and Katherine Warshauer. Partner David R. Bauer and associate Alison T. Chin provided intellectual property advice. The tax team included partner Michael Farber and associate Kelli A. Rivers. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the New York and London offices.